Compare Crispr Therapeutics AG (CRSP) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs SAP SE — how do they compare? Crispr Therapeutics AG trades at $54.31 (market cap $5.23B), while SAP SE trades at $206.4 (market cap $240.81B). The key difference: SAP SE is far larger — about 46× Crispr Therapeutics AG's market cap, and SAP SE pays a 1.4% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | SAP | |
|---|---|---|
Market Cap | $5.23B | $240.81B |
Sector | Health | Technology |
52-Week High | $76.78 | $280.46 |
52-Week Low | $44.34 | $146.38 |
Enterprise Value | $3.65B | $239.52B |
Dividend Yield | — | 1.4% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
